GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Debt-to-Revenue

SpectraScience (SpectraScience) Debt-to-Revenue : N/A (As of Sep. 2017)


View and export this data going back to . Start your Free Trial

What is SpectraScience Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

SpectraScience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $6.51 Mil. SpectraScience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $1.41 Mil. SpectraScience's annualized Revenue for the quarter that ended in Sep. 2017 was $0.00 Mil.


SpectraScience Debt-to-Revenue Historical Data

The historical data trend for SpectraScience's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience Debt-to-Revenue Chart

SpectraScience Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 9.74 N/A 840.43 1,497.00

SpectraScience Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 454.06 N/A N/A N/A N/A

Competitive Comparison of SpectraScience's Debt-to-Revenue

For the Medical Devices subindustry, SpectraScience's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpectraScience's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraScience's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where SpectraScience's Debt-to-Revenue falls into.



SpectraScience Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

SpectraScience's Debt-to-Revenue for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.385 + 1.1) / 0.005
=1,497.00

SpectraScience's annualized Debt-to-Revenue for the quarter that ended in Sep. 2017 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.506 + 1.41) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2017) Revenue data.


SpectraScience Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of SpectraScience's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraScience (SpectraScience) Business Description

Traded in Other Exchanges
N/A
Address
11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121
SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.
Executives
Lowell Giffhorn officer: CFO 10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines